Vaccine News and Research

Latest Vaccine News and Research

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

18 Jun 2012

Scientists discover master regulator gene needed for development of M cells

Scientists have found a master regulator gene needed for the development of M cells, a mysterious type of intestinal cell involved in initiating immune responses.

18 Jun 2012

Opinion pieces address Child Survival Call to Action

The governments of the United States, India, and Ethiopia, in collaboration with UNICEF, on Thursday launched the Child Survival Call to Action in Washington, D.C., during a two-day event that brings together world leaders, public health experts, child health advocates and others in an effort to reduce child mortality to 20 per 1,000 by 2035 worldwide, with the ultimate goal of ending preventable child deaths.

16 Jun 2012

Governments, private sector partners come together at Child Survival Call to Action in Washington

The two-day Child Survival Call to Action, "a conference hosted by the government in collaboration with Ethiopia, India and UNICEF to recognize and promote efforts to curtail child mortality," began in Washington, D.C., on Thursday, the Associated Press/Washington Post reports, noting that U.S. Secretary of State Hillary Clinton and actor Ben Affleck, founder of the Eastern Congo Initiative, "were two of more than 80 governmental, civil society and business leaders slated to speak at the conference Thursday and Friday."

16 Jun 2012

Opinion pieces, blog posts address Child Survival Call to Action

The governments of the United States, India, and Ethiopia, in collaboration with UNICEF, today are scheduled to launch the Child Survival Call to Action in Washington, D.C., a two-day event that brings together world leaders, public health experts, child health advocates and others in an effort to reduce child mortality to 20 per 1,000 by 2035 worldwide, with the ultimate goal of ending preventable child deaths.

15 Jun 2012

NIH awards $9 million grant to study aging and immunity to infections

The Trudeau Institute today announced that faculty member Laura Haynes, Ph.D., was awarded a grant from the National Institutes of Health (NIH) to study how aging impacts the immune system's response to influenza infection and vaccination.

15 Jun 2012

FDA approves GSK’s MenHibrix to treat meningococcal and Hib diseases

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine].

15 Jun 2012

FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

15 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

Researchers identify primary player of the biochemical bugle call

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Embryonic stem cells hold great promise for biomedical science

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.

14 Jun 2012

Brazilian researchers say schistosomiasis vaccine could be available in 3 years

"Brazilian researchers say they have successfully tested a vaccine against schistosomiasis, a disease caused by parasitic worms that afflicts more than 200 million people worldwide," Agence France-Presse reports.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Clinical trials can benefit under-represented populations in developing countries

While conducting more clinical trials in developing countries can help under-represented populations benefit from new medical developments, trials in low-income settings face challenges such as complicated regulations, Trudie Lang of the Centre for Tropical Medicine at the University of Oxford and Sisira Siribaddana of the University of Rajarata and the Institute of Research & Development in Sri Lanka write in an essay published Tuesday in PLoS Medicine.

14 Jun 2012

IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine

Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

14 Jun 2012

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Today, the Sabin Vaccine Institute, in partnership with the George Washington University and the Children's National Medical Center, began vaccinating participants for a Phase 1 clinical trial of a novel human hookworm vaccine.

14 Jun 2012

Inovio to participate at Marcum Microcap Conference, BIO International Convention

Inovio Pharmaceuticals, Inc. announced today that Dr. Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.

14 Jun 2012

Cervical Cancer vaccine, increased awareness could help lower disease rate in Kenya

AllAfrica.com/Guardian examine efforts to prevent and treat cervical cancer among women in Kenya, where an estimated 3,400 women die of the disease each year and only five percent receive screening.

14 Jun 2012